Pharma BD Deal Intelligence
Lundbeck's $1.95B bet on eptinezumab paid off: Vyepti hit DKK 2,909M in FY2024 (+72% CER) and led anti-CGRP growth in the U.S. at 11.2% share by September 2025—though its Phase 2/3 push into episodic cluster headache missed its primary endpoint outright.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Piper Jaffray analyst Danielle Brill said 'we can't imagine any investor wanted to see Alder launch eptinezumab alone'—signaling relief that Lundbeck's…
FiercePharma reported Alder had been seeking only an ex-US partner; Lundbeck escalated to a full buyout, suggesting strategic conviction in IV CGRP…
Vyepti (eptinezumab) revenue reached DKK 2,909 million in FY2024 following an increase of +72% at constant exchange rates; total group revenue a record DKK…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Lundbeck agreed to acquire Alder BioPharmaceuticals for $18.00 per share upfront in cash plus a $2.00 per share CVR tied to FDA approval, totaling up to $1.95B. Lead asset eptinezumab (later approved as Vyepti) is the first IV-administered anti-CGRP monoclonal antibody for migraine prevention. Closed October 2019. Post-close, the thesis has been strongly validated commercially: Vyepti became one of Lundbeck's fastest-growing strategic brands, reaching DKK 2,909M in FY2024 (+72% CER) and DKK 3,254M in the first nine months of 2025 (+57% CER), and was the fastest-growing anti-CGRP in the U.S. at 11.2% market share by September 2025. A label-expansion attempt in episodic cluster headache failed, however: Lundbeck's Phase 2/3 trial (NCT04688775) missed its primary endpoint (-4.0 vs -4.6 weekly attacks for placebo, p=0.5048), so Vyepti remains a migraine-prevention-only asset.
Assessment window: 5yr post-close.
$6.8B Global migraine drugs market 2024
Migraine is a chronic neurologic disorder characterized by recurrent episodes of moderate-to-severe headache, often with photophobia, phonophobia, nausea, and aura. It affects roughly 40 million Americans (~12% prevalence), with 3-4 million suffering chronic migraine (≥15 headache days/month). It is a leading cause of disability among working-age adults and a major driver of healthcare utilization.
At the September 2019 deal announcement, the CGRP migraine-prevention class was a year old and crowded. Three subcutaneous CGRP mAbs were already approved: Amgen/Novartis's Aimovig (erenumab, anti-CGRP receptor, May 2018), Teva's Ajovy (fremanezumab, Sept 2018), and Eli Lilly's Emgality (galcanezumab, Sept 2018). Eptinezumab was first-in-class as an IV-infused, quarterly anti-CGRP antibody, differentiating on rapid onset (efficacy within 24 hours) and adherence guaranteed by site-of-care administration—features that addressed compliance gaps in the SC mAb class. Older preventives included Allergan's Botox (onabotulinumtoxinA) for chronic migraine and oral generics (topiramate, propranolol, amitriptyline). The deal mattered because Lundbeck's neuroscience commercial infrastructure could compete in a crowded class where standalone Alder would have struggled. Piper Jaffray's Danielle Brill said 'we can't imagine any investor wanted to see Alder launch eptinezumab alone'. Vyepti was approved February 2020, has captured roughly 7% volume share by mid-2023, and reached DKK 2.9B in 2024 sales—evidence the deal-time strategic rationale played out, though the new gepant class (Nurtec ODT, Qulipta) and Lundbeck's own 2024 sales trajectory show the field continues to fragment.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| H. Lundbeck A/S / Alder BioPharmaceuticals, Inc. (this deal) | 2019 | $1.9B | — |
| H. Lundbeck A/S / Longboard Pharmaceuticals, Inc. | 2024 | $2.6B | 71 |
| H. Lundbeck A/S / Prexton Therapeutics BV | 2018 | $1.1B | 14 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals | 2015 | $3.5B | 86 |
← Browse all deals · How we score deals
More: 2019 deals · H. Lundbeck A/S deals · Neurology deals